Stephen Leung

BMK2024: We are delighted to invite you to an exclusive tour of the International Vaccine Institute (IVI)’s state-of-the-art laboratories in Seoul on 12th August 2024 in conjunction with 6th Vaccine World East Asia 2024.    This rare opportunity allows you to: -Explore our advanced microbiological, immunological, and genomic containment labs, including BSL-3 and BSL-2 facilities. - Discover how experts in molecular biology, microbial genetics, bioinformatics, and immunology develop and optimize vaccines. - Learn about innovative technologies supporting clinical testing and industrial-scale production. - See the animal facilities and the preclinical studies ensuring vaccine safety. - Understand the process of transferring technology to manufacturers for global vaccine distribution. Want to part of the exclusive tour? Register Here:https://lnkd.in/eWwQDAce #VaccineInnovation #BiomedicalResearch #IVITour #VaccineDevelopment #BiotechConference #HealthTech #GlobalHealth #Immunology #BiotechIndustry #MedicalResearch #SiteTour #IMAPAC

14

The #arthritictherapeutic industry is rapidly evolving with advancements in #personalizedmedicine, #biosimilars, and #cell therapies. Enhanced healthcare infrastructure, particularly in the #AsiaPacific region, is meeting rising demand for effective arthritis management, pioneering improved patient outcomes and quality of life. #AMR #ArthritisTreatment #PersonalizedMedicine #Biologics #HealthcareInnovation #RheumatoidArthritis #Osteoarthritis #Biosimilars #StemCellTherapy #AsiaPacificHealthcare #PatientOutcomes #ChronicDisease #PrecisionMedicine https://lnkd.in/daYTzeXv

5

AstraZeneca to Build $1.5 Billion ADC Production Facility in #Singapore In a move to enhance global supply of its #antibody drug conjugates (ADCs) portfolio, AstraZeneca intends to build a $1.5 billion facility in Singapore for the manufacturing of ADCs. The planned greenfield facility, which according to #AstraZenca is supported by the Singapore Economic Development Board (EDB), will be the company’s first end-to-end ADC production site, fully incorporating all steps of the #manufacturing process at a commercial scale. The process comprises antibody production, synthesis of #chemotherapy drug and linker, conjugation of drug-linker to the antibody, and filling of the completed ADC substance. Pascal Soriot, CEO of AstraZeneca, commented: “AstraZeneca has built an industry-leading portfolio of cancer medicines including antibody drug conjugates which have shown enormous potential to replace traditional chemotherapy for patients across many settings. Singapore is one of the world’s most attractive countries for investment given its reputation for excellence in complex manufacturing, and I am excited for AstraZeneca to locate our $1.5 billion ADC manufacturing facility in the country.” Read more on #CMI online: https://lnkd.in/ewQtNdYZ

1

The Cancer Foundation of China (CFC) has signed a strategic cooperation framework agreement with Asieris Pharmaceuticals (SHSE: 688176) to accelerate efforts toward eliminating cervical cancer. This collaboration combines the strengths of CFC and Asieris Pharmaceuticals to build a comprehensive pathway for prevention and treatment. Key initiatives will include advancing early diagnosis and treatment of precancerous lesions, promoting standardized long-term management practices, and strengthening the capabilities of healthcare institutions. The partnership will also facilitate joint research, professional training, and academic exchanges to support early detection and management of cervical cancer. In select regions, pilot programs will introduce full-chain solutions and new technologies, discovering models for a coordinated approach to cervical cancer prevention and care. #CervicalCancerPrevention #HealthcareInnovation #CancerCare #EarlyDiagnosis #PublicHealth #MedicalAdvancement #QimingPortfolio #QimingHealthcare

1

🔗 Gene Solutions’ Introduction to Medical Societies in Singapore🌐    At the recent BPOF-APGCS - 2nd Biomarkers and Precision Oncology Forum & 11th Asia Pacific Gastroenterology Cancer 2024 Summit in Singapore, Gene Solutions had the privilege of engaging with oncologists across Asia to showcase our trademarked #MCED test, SPOT-MAS, and Minimal Residual Disease #MRD test, K-TRACK.🧬    A key highlight 💡 of our participation was Ms Van Anh Nguyen's, our Oncology Research Associate, sharing of the latest data from the study “Prognostic Value of Post-Operative ctDNA in Solid Tumor Cancers.” Her insights sparked meaningful discussions on how MRD tests like #KTRACK can evaluate treatment responses and accurately monitor the risk of relapse. 📊    We also introduced our #MultiEarlyCancerDetection test, #SPOTMAS, to Singaporean audience, generating significant interest from conference delegates. With our test now available at Gene Solutions Genomics Singapore Lab, healthcare practitioners can access to a valuable tool to screen for 10 common and aggressive cancers that currently lack effective screening methods.    🌟The summit underscored the power of collaborative effort and shared knowledge in enhancing cancer care.   📰Read more at: https://lnkd.in/e8NE_xiX   #GeneSolutionsSingapore #APGCS #BPOF #Oncology #CancerCare #MRD #MinimalResidualDisease #ColorectalCancer #GastricCancer #LiverCancer #HCC #PrecisionOncology #ctDNA #MultiCancerEarlyDetection #MCED Christopher Wong

40

2 Comments

We are glad to have Loya Hirom, Assistant Vice President - Marketing, Oncquest Laboratories Ltd. as a key speaker for #ClinicalTrials Summit 2024 https://lnkd.in/gaFcSFXg For our upcoming conferences visit : https://lnkd.in/gjQY86dn Fen Castro #VIct #clinicalresearch #clinicaloperations #clinicaldevelopment #ClinicalResearchNews  #cro #qualitycontrol #qualityassurance #RegulatoryAffairs #RegulatoryWriting #pharmacovigilance #medicalaffairs #patientsafety #biosimilars #patientsafety #pharmaceuticalmanufacturing #pharmaceuticals #pharmaceuticalindustry #pharmanews #healthcare #medicines #lifesciences #biotech #mumbai 

6

It was a busy week for tech+bio news: 🚀 AstraZeneca plans to build a $1.5 billion manufacturing facility in Singapore for antibody-drug conjugates (ADCs), marking its first end-to-end ADC production site and supported by the Singapore Economic Development Board. The facility, set to be operational by 2029, aims for zero carbon emissions from day one. 🔬 Insilico Medicine, in collaboration with NVIDIA, introduces nach0, a large language model (LLM) for solving biological and chemical tasks, integrating diverse datasets to perform natural language processing and molecular generation, as detailed in Chemical Science Journal. 💰 LabGenius raises £35M in Series B led by M Ventures to advance its ML-driven antibody discovery platform and progress a pipeline of assets towards clinical development, bringing total funding to £58M. 🔬 Sanofi, Formation Bio, and OpenAI announce a first-in-class AI collaboration to accelerate drug development, leveraging proprietary data, AI model customizations, and extensive engineering resources to bring new medicines to market more efficiently. 📈 Tempus AI has filed its S-1 to go public, highlighting its extensive multimodal, de-identified records database, which is over 50 times the size of The Cancer Genome Atlas. ✨ Pharma giants like Merck, J&J, Roche, and Amgen filed quantum computing patents, while Pfizer and IBM collaborate to integrate generative AI and quantum computing to enhance clinical trials. 🔬 Owkin expands its oncology and immunology drug pipeline with the global licensing of OKN4395, a dual EP2/EP4 inhibitor from Idorsia, leveraging advanced AI and multimodal patient data for precision medicine. 💰 Orna Therapeutics acquires ReNAgade Therapeutics, appointing Amit Munshi as CEO and retaining Tom Barnes on the board. The acquisition combines Orna's circular RNA technology with ReNAgade's RNA delivery systems to advance in vivo CAR RNA medicines for oncology and autoimmune diseases. 🚀 Radar Therapeutics launches with $13M to develop RNA sensor programmable technologies, aiming to deliver genetic payloads that activate only in the presence of specific cellular expression signatures. Keep reading weekly roundup by following the link to our latest newseltter Where Tech Meets Bio (link in the comments) 👇 #biotech #technology #deeptech #biopharmatrend

18

2 Comments

#Singapore to house AstraZeneca's first end-to-end antibody drug conjugates (ADCs) #manufacturing facility! 💊🏭 AstraZeneca, a global #biopharmaceutical leader, is set to build a US$1.5 billion facility for producing ADCs–a next-generation cancer treatment. This facility will be a first for AstraZeneca, marking a major leap in biopharmaceutical manufacturing. This investment signifies a significant boost for industries in the life sciences sector. Here's how: 👨🏻‍💻 Skilled workforce: The facility will need scientists, engineers, and digital specialists, creating opportunities for recruitment and training companies. 🛠️ Supporting industries: The project will drive demand for suppliers and service providers across sectors in logistics, engineering, etc. 🤖 Tech adoption: The focus on automation and AI highlights the need for digital solutions, presenting opportunities for businesses offering these technologies. This #investment reinforces Singapore's reputation as a leader in advanced manufacturing and biopharmaceuticals. Businesses can capitalise on this momentum by positioning themselves as key partners in this thriving sector, driving #growth and #innovation. ✨ Ready to unlock your #SME’s growth potential? Book a complimentary 1-to-1 #business advisory session here: https://lnkd.in/g_5tassX and let SME Centre@SMF (Singapore Manufacturing Federation) guide you towards new heights of innovation and success. 💡🚀 #smes #smesupport #support #businessgrowth #sgbusiness #businessadvisory #consulting #businessstrategy #biopharmainnovation #industrialtransformation #advancedmanufacturing #manufacturingtransformation #smartmanufacturing #technology #digitalisation #digitalization #digitalsolutions #industrialautomation #digitaltransformation

7

🌍 BPI Boston 2024: A Global Celebration of Biotechnology and Pharmaceutical Innovation! 🌍 This week, we had an incredible time at BPI Boston 2024, where the world's leading minds in biopharma came together to explore, innovate, and collaborate! 🌟 The conference was a dynamic platform for discussing the fascinating journey of small and large molecules from the laboratory to the market. 🔬 Key Highlights: 🖊 Insightful Sessions: Engaging talks on the latest advancements in small and large-molecule therapeutics at various stages from discovery to commercialization. 🖊 Interactive Panels: Experts shared their experiences and strategies for overcoming challenges in drug development and regulatory pathways. 🖊 Customer Engagement: We were thrilled to connect with so many of you and discuss your novel molecule needs and how we can accelerate their journey from lab to market. 🖊 Networking Opportunities: The event facilitated meaningful connections, fostering collaborations that will drive the industry forward. 🖊 A heartfelt thank you to all the attendees, speakers, and organizers for making this convention a tremendous success. Let’s continue to break new ground in biopharma together! 🚀 Now, our discovery team is gearing up for the next exciting event: Discovery on Target 2024! 🎉 Join us at Booth #424 from September 30 to October 3 at the Sheraton Boston, where we will showcase our latest advancements in biologics and small molecules. With Aurigene's comprehensive capability to support from discovery to commercial-scale cGMP manufacturing, expertise across diverse biologics modalities, and small molecule discovery in both chemistry and biology, we are well suited to taking your molecule from lab to market faster. Write to us at [email protected] to book a meeting with our experts attending the DOT conference in Boston. Meet our experts by visiting Booth #424 or drop an email to schedule a meeting. See you soon! #BPIBoston #BiotechInnovation #DrugDevelopment #Biopharma #Networking #DiscoveryOnTarget #DOT2024 #Biologics #SmallMolecules #LabToMarket #Aurigene #PharmaConference Roger Lias Jenny Yip

141

3 Comments

𝐍𝐞𝐰 𝐌𝐇𝐋𝐖 𝐆𝐮𝐢𝐝𝐚𝐧𝐜𝐞 𝐀𝐢𝐦𝐬 𝐭𝐨 𝐅𝐚𝐜𝐢𝐥𝐢𝐭𝐚𝐭𝐞 𝐈𝐧𝐜𝐥𝐮𝐬𝐢𝐨𝐧 𝐨𝐟 𝐉𝐚𝐩𝐚𝐧𝐞𝐬𝐞 𝐏𝐚𝐫𝐭𝐢𝐜𝐢𝐩𝐚𝐧𝐭𝐬 𝐢𝐧 𝐆𝐥𝐨𝐛𝐚𝐥 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬 The Ministry of Health, Labour and Welfare (𝐌𝐇𝐋𝐖) in Japan is transforming global clinical trials with its groundbreaking new guidance. Traditionally, sponsors faced delays as they conducted additional phase 1 studies with Japanese participants before including 𝐉𝐚𝐩𝐚𝐧 𝐢𝐧 𝐠𝐥𝐨𝐛𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬. This outdated approach often slowed down the approval of new medicines in Japan. Now, 𝐌𝐇𝐋𝐖 is paving the way for a more efficient process. By removing the requirement for additional phase 1 studies for drugs where early clinical development is occurring outside Japan, the new guidance aims to expedite drug development. This means faster access to innovative treatments for Japanese patients and a more streamlined global trial process. This initiative not only accelerates drug development but also fosters greater inclusion of Japanese participants in global studies, ensuring diverse and comprehensive data. 𝐀𝐮𝐭𝐡𝐨𝐫: HASEGAWA Mayumi 🔗 𝐋𝐞𝐚𝐫𝐧 𝐌𝐨𝐫𝐞:  https://lnkd.in/gqFDF2MR 🔗 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐲𝐨𝐮𝐫 𝐜𝐨𝐩𝐲 𝐡𝐞𝐫𝐞: https://lnkd.in/gTCs4cpe #ClinicalTrials #DrugDevelopment #MHLW #PharmaInnovation #GlobalHealth #ClinicalResearch #JapanHealthcare #PharmaNews #MedicalInnovation #HealthcareRevolution #Biotech #Pharmaceuticals #HealthPolicy #GlobalTrials #InnovationInHealth

5

🎙 Nucleate Singapore Pulse 🔬 This month, Nucleate Singapore was thrilled to interview Dr. David M Epstein, co-founder and president of PairX Bio, a company spun out from Duke-NUS Medical School pioneering the next generation of cancer-selective biologics. David shares his inspiring journey from a chemist and biophysicist to a biotech leader, emphasizing the importance of following the science and embracing transparency in both academia and industry. 🎧 In this insightful episode, David discusses how PairX Bio is revolutionizing cancer treatment by focusing on the transcriptome instead of the genome. He explains how targeting cancer-specific alternative splicing variants can lead to broader patient populations benefiting from targeted therapies. David also delves into the challenges and strategies of managing investor relations, spinning out from academia, and the nuances of IP patenting. Furthermore, he shares his vision for the future of Singapore's biotech ecosystem, highlighting its growth and potential. David's passion for science and commitment to improving patient care shine throughout the conversation, offering valuable lessons for aspiring scientists and entrepreneurs alike. Listen and follow us on Spotify 👉https://lnkd.in/gyrP7TJY and Apple Podcasts 👉https://lnkd.in/gTa3jgF4 Show notes and transcripts 👉 https://lnkd.in/gwnAk3BU Podcast team: John Joson Ng, Hana Maldivita Tambrin, PhD, Dillon Chew, and Aakash Kumar Nucleate team: Ying Tong Yeo, Jessie Wong Ling Ai, Samantha Wong, PhD, Ivan Seah, MBBS/MBA/MPH, Jiaqi Liang, Damien Chua, Shruti Sridhar, Gloria Chan, Isha Karnik, Senuri De Silva, Panida Cen, Jashan Singh, Roshni Gupta, Diya Srivastava, Dijin Zhang, Devika Menon #Cancer #Immunotherapy #Cancertreatment #Transcriptome #Therapeutics #Intellectualproperty #Patents #Nucleate #Podcast

92

5 Comments

Eri Sekine, Executive Vice President, CMIC Group, will be chairing a Forum Presentation at DIA on Tuesday, June 18th at 1:15 pm. The session, titled “Enabling Patient Access Worldwide Including Japan or Other Countries to Innovative Drugs Through Global Development Strategy,” will delve into strategies for maximizing global patient access and business opportunities through effective global development approaches. 📅 Date and Time: Tuesday, June 18th at 1:15 pm 📌 Experts from pharma and biotech sectors will share insights on: - Maximizing the value of innovative products for the global market - Applying clinical development strategies to expand the target market effectively - Influencing regulators, industry, and trial sites to improve the local environment for global simultaneous development Visit booth #1107 after the presentation to ask any questions and continue the discussion. #DIA2024 #GlobalDevelopment #PharmaInnovation #PatientAccess #CMICGroup #Pharmaceuticals #Biotech #ClinicalDevelopment

58

The first annual syndicated tracker covering up-to-date engagement landscape among oncology experts in Asia is coming soon ... 👀 Stay tuned for more updates! #MIMS #oncology #oncologistengagement #promotracker #Asia #marketresearch #insights #trends #launch

42

1 Comment

Making an impact on patients' lives by developing better ways to treat lymphoma and colorectal cancer in Singapore. IMCB is proud to be part of two recently awarded NRF OF-LCG projects led by National Cancer Centre Singapore, SYMPHONY 2.0 and Colo-SCRIPT. The OF-LCG grant call supports patient-centric translational research with the goal of advancing human health and wellness and creating economic value. These projects are made possible through the collaboration between National Cancer Center Singapore, National University of Singapore, National University Healthcare System, Nanyang Technological University (NTU), Singapore General Hospital (SGH) and our fellow A*STAR sister institutions, Bioinformatics Institute, A*STAR, Genome Institute of Singapore (GIS) and Singapore Immunology Network. A huge congratulations to our Principal Investigators, Dr Valerie Yang (SYMPHONY 2.0), Prof Ashok Venkitaraman, Prof Vinay Tergaonkar and Prof Qi-Jing Li. Read more about the work here: https://lnkd.in/g9FvVuqq #IMCBastar #IMCBscience #IMCBcollab #lymphoma #colonrectalcancer #patienthealth #cancer

102

2 Comments

The National Medical Products Administration has granted priority review for Belief BioMed's BBM-H901 Injection New Drug Application (NDA). This milestone for the gene therapy product, developed and produced by Belief BioMed, represents a significant advancement in treating hemophilia B in adult patients. Delivered via intravenous injection, BBM-H901 introduces the human coagulation factor IX gene to sustain and elevate coagulation levels, helping to prevent bleeding in patients with hemophilia B. Its inclusion in the priority review process underscores its clinical value and accelerates its approval timeline. #GeneTherapy #HemophiliaB #NMPA #NewDrugApplication #HealthcareInnovation #Biotechnology #ClinicalTrials #PriorityReview #MedicalResearch #QimingPortfolio #QimingHealthcare

1

Simcere Zaiming, the innovative #Oncology division of Simcere Pharmaceutical Group, has announced a #CollaborationAgreement with Shenzhen TargetRx, Inc. This #Partnership focuses on #TGRX326, a clinical-stage #AntiTumor candidate that serves as a dual receptor #TyrosineKinaseInhibitor for #ALK and #ROS1. Under the agreement, #SimcereZaiming will secure exclusive #CommercialRights to #TGRX326 in #MainlandChina. These rights include #MarketingPromotion, #StrategyDevelopment, and the right to benefit from #TGRX326. As part of the deal, #TargetRx will receive an initial payment of over $20 million and will compensate #SimcereZaiming for its #PromotionalEfforts. #TGRX326, a third-generation #AnaplasticLymphomaKinase (#ALK) inhibitor, was independently developed by #TargetRx. This potent and highly selective #SmallMolecule inhibitor targets #ALK and #cROS1 (#ROS1) #ReceptorTyrosineKinases (#RTKs), offering significant therapeutic potential for patients with #ALKROS1 #FusionGenePositive #NonSmallCellLungCancer (#NSCLC), especially those who have developed resistance due to #ALKMutations, including #G1202R. #CancerTreatment #LungCancer #PharmaInnovation #Biotech #TargetedTherapy #PrecisionMedicine #Pharmaceuticals #CancerResearch #OncologyBreakthroughs #RASLifeScienceSolutions #MarketIntelligence #MarketResearch #CompetitiveIntelligence #StrategySupport #PortfolioOptimization For detailed news: https://lnkd.in/dWqFKxAt Follow our page for more industry updates: https://lnkd.in/de5zNWmK

16

🚀 Exciting Insights into GLP-1R Agonists for Type 2 Diabetes and Obesity! Our latest report provides a comprehensive overview of GLP-1R agonists, covering epidemiology, symptoms, diagnosis, and disease management. 📊 It includes annualized market revenue, cost of therapy, and treatment usage patterns forecasted from 2023 to 2033. 🗓️ Dive into strategic competitor assessments, market characterization, and unmet needs. 🔍 Explore emerging trends and dual/triple mechanisms of action in development for type 2 diabetes and obesity. 🌐 Don't miss the insightful review of key industry drivers, restraints, and challenges! 📈 https://lnkd.in/gbTyhs-c #DiabetesCare #ObesityTreatment #GLP1R #HealthcareInnovation #MarketAnalysis #EmergingTrends #ClinicalTrials

15

1 Comment

🚀 A big shout to Llinks Team Advice on Strategic Biopharma Collaboration, Strengthening Shanghai Allist Pharmaceuticals Co., Ltd’s Oncology Pipeline 🚀 Shanghai Allist Pharmaceuticals Co., Ltd (688578.SH) has signed a strategic collaboration with Jacobio Pharma (1167.HK), securing exclusive rights in Greater China for the KRAS G12C inhibitor Goralresib and SHP2 inhibitor JAB-3312. This partnership strengthens Allist's cancer treatment pipeline, with Goralresib already under priority review and JAB-3312 in Phase III trials. 💼 This partnership not only strengthens Allist’s oncology pipeline, targeting lung, pancreatic, and colorectal cancers, but also positions us to bring innovative treatments to patients in need. Notably, Goralresib's New Drug Application for second-line NSCLC with KRAS G12C mutation has received priority review as of May 21, 2024. Meanwhile, JAB-3312, as the first SHP2 inhibitor to enter a pivotal clinical trial, is set to offer a new treatment option with its unique “dual oral therapy” approach. 🎯 In this significant transaction, Llinks legal team(Head partner Xun Yang) provided comprehensive legal services to Allist Pharmaceuticals. From strategizing and drafting the licensing agreement to negotiations and advising on critical issues such as international multicenter cooperation and clinical development handover, Llinks' expertise has once again been integral in driving forward Allist's business development (BD) initiatives. 🔑 #AllistPharma #JACOBIOPharma #OncologyInnovation #LegalServices #TechLaw #Biopharma #StrategicPartnership #ClinicalTrials #KRASG12C #SHP2Inhibitor #Oncology #Biopharma #LegalServices #StrategicPartnership #ClinicalTrials #Innovation

4

1 Comment